The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, received a $325,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on April 15, 2024. The award is funded through the NIDDK's Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), which supports comprehensive research across medical disciplines related to understanding, preventing, and treating diseases of the diabetes, digestive, and kidney systems.
The goal of this award is to generate pilot and feasibility data required to design and lead a definitive randomized controlled trial examining the potential benefits of combination therapy using levothyroxine (LT4) and triiodothyronine (LT3) for the treatment of hypothyroidism. The research aims to refine the study population, dosing strategy, outcome measures, and statistical power analysis to inform the future full-scale clinical trial. This work will help determine whether a more physiologic thyroid hormone replacement regimen that includes both LT4 and LT3 would benefit patients with residual hypothyroid symptoms despite standard LT4 therapy.
Generated 2/25/25, 4:40 AM